Compare
ENDRA Life Sciences Inc. vs Nuwellis, Inc. vs Neuraxis, Inc vs ADM Tronics Unlimited, Inc.
| Latest fiscal year | ENDRA Life Sciences Inc. NDRA | Nuwellis, Inc. NUWE | Neuraxis, Inc NRXS | ADM Tronics Unlimited, Inc. ADMT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | n/a | $8.27M | $3.57M | $3.35M |
| Revenue growth (YoY) | n/a | -5.4% | +32.9% | +4.7% |
| Gross margin | n/a | 62.0% | 84.2% | 40.5% |
| Operating margin | n/a | -134.3% | -219.4% | -4.8% |
| Net margin | n/a | -211.9% | -218.5% | -3.0% |
| Net income | -$7.03M | -$17.52M | -$7.80M | -$100.4K |
| EPS (Diluted) | -$8.93 | -$25.39 | -$0.95 | $0.00 |
| Operating cash flow | -$5.18M | -$10.81M | -$6.43M | -$124.1K |
| Free cash flow | -$5.20M | -$10.90M | -$6.46M | n/a |
| Cash & equivalents | n/a | $1.08M | $4.97M | $255.7K |
| Total assets | $3.85M | $6.12M | $6.40M | $1.83M |
| Total liabilities | $1.59M | $3.49M | $3.00M | $1.26M |
| Shareholders' equity | $2.26M | $2.62M | $3.40M | $571.0K |
| Return on year-end equity | -310.9% | -667.7% | -229.5% | -17.6% |
| Shares outstanding | 1.18M | 1.69M | 10.65M | 67.59M |
Revenue, most recent five fiscal years
| Fiscal year | ENDRA Life Sciences Inc. | Nuwellis, Inc. | Neuraxis, Inc | ADM Tronics Unlimited, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $8.27M Ended 2025-12-31 | $3.57M Ended 2025-12-31 | $3.35M Ended 2026-03-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $8.74M Ended 2024-12-31 | $2.69M Ended 2024-12-31 | $3.20M Ended 2025-03-31 |
| 2 years earlier | $6.2K Ended 2018-12-31 | $8.86M Ended 2023-12-31 | $2.46M Ended 2023-12-31 | $2.97M Ended 2024-03-31 |
| 3 years earlier | $351.6K Ended 2017-12-31 | $8.54M Ended 2022-12-31 | $2.68M Ended 2022-12-31 | $3.68M Ended 2023-03-31 |
| 4 years earlier | $515.6K Ended 2016-12-31 | $7.92M Ended 2021-12-31 | n/a | $3.21M Ended 2022-03-31 |